Meda Pumps Up Iron With Feosol Relaunch, Revamps Neglected OTCs
This article was originally published in The Tan Sheet
Meda Consumer Healthcare is relaunching the Feosol iron supplement brand with three SKUs and aims to become the clear No. 1 brand in the category. Meda’s Swedish parent company prioritizes OTC growth through brand acquisitions and increased marketing resources.
You may also be interested in...
Omega Pharma will pay $619 million for GSK’s Lactacyd feminine wash products, Abtei supplements, Solpadeine analgesics, Zantac antacid, Nytol sleep aids and the allergy drug Beconase. The deal is part of Glaxo’s plan to simplify its consumer business by selling 19 OTC brands.
GSK comments on nicotine’s status; Perrigo launches formula; NAI sales up with licensing revenue; Japanese star anise is adulterant; POMx for sale; toothpaste nurdle suit settled; Virility Max recalled
Meda's acquisition of fast-growing Swedish OTC firm Antula Healthcare brings on board "proven" marketing expertise to boost existing product sales, a well-established nonprescription drug portfolio and a prolific pipeline for long-term growth.